Comparative Pharmacology
Head-to-head clinical analysis: BESREMI versus PEGINTRON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BESREMI versus PEGINTRON.
BESREMI vs PEGINTRON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BESREMI (ropeginterferon alfa-2b) is a recombinant interferon alfa-2b conjugated to a 40 kDa polyethylene glycol (PEG) moiety. It binds to interferon alpha receptors (IFNAR1/IFNAR2), activating JAK-STAT signaling, leading to expression of interferon-stimulated genes with antiproliferative, antiviral, and immunomodulatory effects. Specifically, it suppresses the proliferation of hematopoietic progenitor cells, reduces JAK2V617F allele burden, and normalizes blood counts in polycythemia vera.
Recombinant interferon alfa-2b conjugated to polyethylene glycol; binds to interferon receptors, inducing antiviral, antiproliferative, and immunomodulatory effects via JAK-STAT signaling pathway.
Subcutaneous injection of 250 to 350 mcg once every two weeks, with titration based on platelet counts and tolerability.
1.5 mcg/kg subcutaneously once weekly in combination with oral ribavirin.
None Documented
None Documented
Terminal half-life approximately 50-100 hours (mean 70 h) in healthy volunteers; in patients with polycythemia vera, half-life is 50-80 hours, supporting once-weekly dosing.
Terminal half-life: 40 hours (range 30-50 h) after subcutaneous dosing; supports weekly dosing regimen
Primarily renal (clearance 0.5 L/h/kg), with <1% excreted unchanged in urine; remainder metabolized via proteolysis to small peptides and amino acids.
Renal: 30% unchanged; biliary/fecal: 70% as metabolites and parent drug
Category C
Category C
Interferon
Interferon